Scaling MLR Review for a Launch: Internal, Outsourced, or Hybrid?

A product launch is where MLR review goes from a steady annoyance to an outright bottleneck. Content volume multiplies, every asset is new and unapproved, and the same review function that handled a manageable trickle is suddenly the gate the whole launch waits on. The uncomfortable question every commercial team eventually faces is simple: when the work triples, how do you scale the review without scaling your timeline with it?

There are only three real levers, more people, outside help, or better tools, and most teams reach for them in exactly the wrong order. Here is the honest trade-off on each, and the reframe that makes the whole question easier.

The surge nobody plans for

The first problem is that most teams have no plan at all. Asked how they cope with the increased MLR workload during launches and other high-demand periods, the most common answer by far was simply to absorb it: 53% said their existing staff take on the extra work. Another 17% admitted that scalability is a real challenge they have no solution for. Only a small minority had a deliberate strategy.

Absorbing it is not free. It is paid for in extra review rounds, slipped launch dates, and the evenings and weekends of people who were already busy. "We will just power through" is the default, and it is the most expensive option on the table.

Lever 1: Add internal capacity

The instinct is to hire: more reviewers, or a dedicated promotional-review team, owned and trained in-house.

The upside is real, with control, consistency, and institutional knowledge that compounds. About 30% of MLR professionals expect a centralized, dedicated internal team to be the most effective model going forward, and for high, steady volume it often is.

The catch is that internal capacity is slow and rigid. Experienced medical reviewers are hard to hire and harder to spare, a launch surge is temporary while a headcount is permanent, and the budget rarely cooperates. When money tightens, hiring freezes hit first, even as the work keeps coming. Notably, tooling for content creators often survives a freeze that blocks new headcount, which is worth remembering when you plan.

Lever 2: Outsource the overflow

The flexible answer is to hand the surge to a medical-communications agency or a network of freelance writers. It spins up fast and flexes back down when the launch settles, which is exactly what a temporary spike calls for. About 18% of teams turn to third-party providers to scale, and 12% see specialized external partners as their future model.

But outsourcing capacity is not the same as outsourcing the problem, and this is where teams get burned. Work that comes back from a vendor is not automatically review-ready. Reviewers tell stories of agencies citing the wrong region's label for a claim, or offering a patient-education webpage as the source for a clinical statement, the kind of error that generates more review, not less. The common result is a "human firewall": the company's own staff quietly redoing the vendor's referencing and uploads before anything reaches Veeva. Outsource capacity without controlling quality and you have not removed the bottleneck. You have moved it, and added a markup.

Lever 3: Invest in tooling

The third lever is the least used and, done right, the highest-leverage. Only about 5% of teams said they meet rising demand by investing in technology or process, the smallest slice of all.

That is striking, because tooling is the only lever that reduces the amount of review work rather than just redistributing it. More staff and more vendors both add capacity to do the same work; software that makes each submission review-ready at the source changes how much work there is to begin with. It is underused mostly because adding bodies is easier to approve than changing a process, but bodies do not fix the underlying inefficiency, and they walk out the door when the contract ends.

The model most teams are converging on: hybrid

Ask where MLR is heading, and the single most popular answer is not any one lever. It is a blend: 39% of professionals expect a hybrid of internal and external resources to be the most effective model over the next year or two, ahead of any pure approach.

That makes sense, because each lever covers the others' weakness: internal ownership for control and knowledge, external capacity for the surge, and tooling to hold quality steady across both. But hybrid has one hard requirement that teams underestimate. It only works if a claim written by a freelancer at 11pm is held to the same standard as one written by your senior medical writer, which means a shared, enforced definition of "ready." Without that, hybrid is just inconsistency with more invoices. A maintained core-claims library is part of the answer; a tool that enforces review-readiness regardless of who did the writing is the other part.

The reframe: scale by needing less review

Here is the shift that makes the whole decision easier. Most teams treat MLR scaling as a capacity problem: how to do more review. The cheaper framing is to do less.

The time a piece takes to review depends far less on its length than on its quality: a clean, linked and anchored submission is a quick verification, while a sloppy one can consume a reviewer's weekend. Make every submission arrive review-ready and you have not only added capacity; you have shrunk the work each lever has to handle. Your existing team scales further. Your outsourced overflow is safe to trust. Your tooling spend pays for itself in cycles avoided.

This is the gap PharmaText.ai closes. By checking every claim against its sources and anchoring the evidence at the point of writing, it makes content review-ready before it is ever submitted, whether it came from your team, an agency, or a freelancer. That is how you absorb a launch surge without tripling the review team or betting the timeline on a vendor: not by reviewing faster, but by sending less broken work to review in the first place.

Sources: MLR workload, scaling, and future-model figures from a 2024 industry webinar by Impatient Health; review-time-by-quality data from the Medical Affairs workload overview by Maaike Addicks, medicalaffairs.nl (2025).